Literature DB >> 649734

Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs.

P O Lagerström, B A Persson.   

Abstract

High-performance liquid chromatography has been employed in the development of assay methods for six antiarrhythmic drugs, disopyramide, lidocain, tocainide, procainamide, aprinidine and quinidine. Liquid-solid chromatography has been used and separation times of about 5 min have usually been sufficient. Owing to the capacity of the liquid chromatographic system, sample preparation has been minimized to a single extraction and direct injection of a considerable part of the extract. The overall time of analysis is very short and the methods are well suited for monitoring of plasma levels of the antirrhythmic drugs and in some instances (procainamide and disopyramide) also for their main metabolites. UV detection at the optimal wavelength has permitted determinations down to 50 pmole (20 ng) in 1 ml of plasma for the amines with high absorbance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 649734     DOI: 10.1016/s0021-9673(00)80996-6

Source DB:  PubMed          Journal:  J Chromatogr


  11 in total

1.  High-performance liquid chromatographic analysis of tocainide in human plasma.

Authors:  L Conings; N Verbeke
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

2.  The measurement of lignocaine at low concentrations in plasma, a comparison of gas liquid chromatography with enzyme immunoassay.

Authors:  S Jain; A Johnston
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

4.  Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.

Authors:  G Forssell; C Graffner; R Nordlander; O Nyquist
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

5.  Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.

Authors:  D Oltmanns; A Pottage; W Endell
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

7.  Lack of an interaction between propranolol and sumatriptan.

Authors:  A K Scott; T Walley; A M Breckenridge; L F Lacey; P A Fowler
Journal:  Br J Clin Pharmacol       Date:  1991-11       Impact factor: 4.335

8.  Comparative class 1 electrophysiologic and anticholinergic effects of disopyramide and its main metabolite (mono-N-dealkylated disopyramide) in healthy humans.

Authors:  L Bergfeldt; K Schenck-Gustafsson; R Dahlqvist
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

9.  Stereoselective disposition of RS-tocainide in man.

Authors:  K J Hoffmann; L Renberg; C Bäärnhielm
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jul-Sep       Impact factor: 2.441

10.  Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis.

Authors:  U Wiegers; P Hanrath; K H Kuck; A Pottage; C Graffner; J Augustin; M Runge
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.